Rocuronium Bromide Injection
Product Images NDC 71872-7317

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 71872-7317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medical Purchasing Solutions, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

7317.pdp (7317)

Rocuronium Bromide Injection 10 mg/mL in a 5 mL multiple dose vial. The label states the strength as 50 mg per 5 mL, for intravenous use only, with a warning about paralysing agents and respiratory arrest. It includes storage instructions to refrigerate at 2° to 8°C, usage conditions, and manufacturer information for Hikma Farmacêutica S.A. (Portugal) and distributor details for Medical Purchasing Solutions, Scottsdale, AZ.*

FDA Label Image

Rocuvial.pdp (Rcouvial)

Label for Rocuronium Bromide Injection, containing 50 mg per 5 mL (10 mg/mL) in a 5 mL multiple dose vial. The label indicates it is for intravenous use only and is a prescription paralyzing agent. It is labeled by Medical Purchasing Solutions, LLC and includes a warning about its paralyzing effect.*

FDA Label Image

Rocuronium Bromide Chemical Structure (Rocuronium Bromide Injection 1)

Chemical structure diagram of rocuronium bromide showing its steroidal backbone with attached functional groups, including a quaternary ammonium ion and a bromide counter ion.*

FDA Label Image

Figure 1: Time To 80% Or Greater Block Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium Bromide Injection 2)

A scatter and box plot chart depicting data in minutes versus dose in mg/kg across three age groups (18-64 years, 65 years and older, and 1-12 years). The y-axis represents time in minutes, and the x-axis shows dosage categories. Individual data points and box plots visualize variability in response time for each dose and age group.*

FDA Label Image

Figure 2: Duration Of Clinical Effect Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium Bromide Injection 3)

A box plot comparing data in minutes across different age groups and dosages labeled in mg/kg. Groups include ages 18-64 years, 65 years and older, 3 months to 1 year, and 1 to 12 years, each with various mg/kg dosages shown on the x-axis. The y-axis represents time in minutes, ranging from 0 to 160.*

FDA Label Image

Figure 3: Duration Of Clinical Effect Vs. Number Of Rocuronium Bromide Maintenance Doses, By Dose (Rocuronium Bromide Injection 4)

A line graph comparing the variable marked as minutes on the Y-axis against dose number on the X-axis for two dose groups labeled .1 mg/kg and .15 mg/kg. The graph shows data points over five doses with sample sizes of N=29 and N=13 respectively, depicting changes in minutes over repeated doses for each group.*

FDA Label Image

Layout 1 (Rocuronium Bromide Injection 9)

The image shows a label for Rocuronium Bromide injection, 10 mg/mL, intended for intravenous use. It features a QR code and alphanumeric identifiers including GTIN 00301234567896, serial number, expiration date placeholder, and lot number. The label is associated with Medical Purchasing Solutions, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.